Molecular profile of salivary gland tumors: discovering new targets for therapy

Introduction. Due to variety of morphological subtypes and poor clinical response, comprehensive molecular profiling for salivary gland cancers become a part of treatment strategy for chemotherapy-resistant cases. Tumors of the salivary glands include more than 20 histological types distinguished by their biological characteristics, response to therapy, and prognosis. The search for specific therapeutically significant markers and mutations for various histological types of salivary gland tumors may allow the development of a diagnostic algorithm and improve patient treatment results.

Aim. To search for therapeutically significant molecular and genetic targets and immunohistochemical markers in various histological types of malignant salivary gland tumors.

Materials and methods. We analyzed data on 280 patients with unresectable recurrent and metastatic salivary gland cancer to identify the main characteristic therapeutically significant immunohistochemical (androgen receptor (AR), epidermal growth factor receptor type 2 (HER2neu), epidermal growth factor receptor (EgfR), programmed cell death receptor 1 (pD-L1) (CpS), сD117, estrogen receptor (ER), progesterone receptor (pR), pan-TRk) and molecular genetic targets (ALK, BRAF, ERBB2, KIT, MET, RET, ROS1, SMO, AR, HRAS, PIK3CA, PDGFRA, NTRK1-3) depending on the histological subtype of the tumor.

Results. Based on the results obtained, in comparison with previous studies, a greater diversity of therapeutically significant mutations, fusions and immunohistochemical markers was revealed for various histological types of tumors. Interestingly, increased expression of AR was detected not only in salivary duct carcinoma, but also in carcinoma ex pleomorphic adenoma, adenocarcinoma not otherwise specified, myoepithelial, mucoepidermoid, adenoid cystic, acinic cell, polymorphous adenocarcinomas. ETV6-NTRK3 gene fusions in addition to secretory carcinoma were detected in mucoepidermoid and salivary duct carcinomas. mutations and fusions in the RET gene have been identified in ductal and mucoepidermoid carcinomas, as well as adenocarcinoma not otherwise specified.

Conclusion. The results of the study allow to expand the group of patients for molecular genetic and IHC testing in order to individualize therapy.

1. Salivary-glands. Сancer today. GLOBOCAN, 2022. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/2-salivary-glands-fact-sheet.pdf.

2. WHO classififcation of tumours editorial board. Head and neck tumours. 5th edn. Lyon: IARC, 2022.

3. Skalova A., Hyrcza M.D., Leivo I. Update from the 5th edition of the world health organization classification of head and neck tumors: salivary glands. Head Neck Pathol 2022;16(1):40–53. DOI: 10.1007/s12105-022-01420-1

4. Rossi E.D., Baloch Z., Pusztaszeri M., Faquin W.C. The Milan system for reporting salivary gland cytopathology (MSRSGC): an ASC-IAC-sponsored system for reporting salivary gland fineneedle aspiration. J Am Soc Cytopathol 2018;7(3):111–8. DOI: 10.1016/j.jasc.2018.02.002

5. Toper M.H., Sarioglu S. Molecular pathology of salivary gland neoplasms: diagnostic, prognostic, and predictive perspective. Adv Anat Pathol 2021;28(2):81–93. DOI: 10.1097/PAP.0000000000000291

6. Andreasen S., Kiss K., Mikkelsen L.H. et al. An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. APMIS 2019;127(5):240–64. DOI: 10.1111/apm.12901

7. Żurek M., Fus Ł., Niemczyk K., Rzepakowska A. Salivary gland pathologies: evolution in classification and association with unique genetic alterations. Eur Arch Otorhinolaryngol 2023;280(11): 4739–50. DOI: 10.1007/s00405-023-08110-w

8. Locati L.D., Ferrarotto R., Licitra L. et al. Current management and future challenges in salivary glands cancer. Front Oncol 2023;13:1264287. DOI: 10.3389/fonc.2023.1264287

9. Laurie S.A., Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24(17):2673–8. DOI: 10.1200/JCO.2005.05.302

10. Airoldi M., Pedani F., Succo G. et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatinin patients with recurrent salivary gland malignancies. Cancer 2001;91(3): 541–7. DOI: 10.1002/1097-0142(20010201)91:3<541::aid-cncr1032>3.0.co;2-y

11. Gilbert J., Li Y., Pinto H.A. et al. Phase II trial of taxol in salivarygland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006;28(3):197–204. DOI: 10.1002/hed.20327

12. Suen J.Y., Johns M.E. Chemotherapy for salivary gland cancer. Laryngoscope 1982;92(3):235–9. DOI: 10.1288/00005537-198203000-00003

13. Ferrarotto R., Heymach J.V. Taking it up a NOTCH: a novel subgroup of ACC is identified. Oncotarget 2017;8(47):81725–6. DOI: 10.18632/oncotarget.20879

14. Ferrarotto R., Mitani Y., Diao L. et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors. J Clin Oncol 2017;35(3):352–60. DOI: 10.1200/JCO.2016.67.5264

15. Ferrarotto R., Mitani Y., McGrail D.J. et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res 2021;27(3):852–64. DOI: 10.1158/1078-0432.CCR-20-1192

16. Ferrarotto R., Eckhardt G., Patnaik A. et al. A phase I doseescalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 2018;29(7):1561–8. DOI: 10.1093/annonc/mdy171

17. Ferrarotto R. 1789P The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors. Ann Oncol 2021;32:S1222. DOI: 10.1016/j.annonc.2021.08.1732

18. Ferrarotto R. Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/ metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). J Clin Oncol 2022;40:6046. DOI: 10.1200/JCO.2022.40.16_suppl.6046

19. Humtsoe J.O., Kim H.S., Leonard B. et al. Newly identified members of FGFR1 splice variants engage in cross-talk with AXL/ AKT axis in salivary adenoid cystic carcinoma. Cancer Res 2021;81(4):1001–13. DOI: 10.1158/0008-5472.CAN-20-1780

20. Ferrarotto R., Sousa L.G., Feng L. et al. Phase II clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol 2023;41(15):2843–51. DOI: 10.1200/JCO.22.02221

21. Tchekmedyian V., Sherman E.J., Dunn L. et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 2019;37(18):1529–37. DOI: 10.1200/JCO.18.01859

22. Cavalieri S., Platini F., Bergamini C. et al. Genomics in nonadenoid cystic group of salivary gland cancers: one or more druggable entities? Expert Opin Investig Drugs 2019;28(5):435–43. DOI: 10.1080/13543784.2019.1598376

23. Boon E., van Boxtel W., Buter J. et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in the Netherlands. Head Neck 2018;40(3):605–13. DOI: 10.1002/hed.25035

24. Locati L.D., Cavalieri S., Bergamini C. et al. Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial. J Clin Oncol 2021;39(36):4061–8. DOI: 10.1200/JCO.21.00468

25. Haddad R., Colevas A.D., Krane J.F. et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39(7):724–7. DOI: 10.1016/s1368-8375(03)00097-6

26. Takahashi H., Tada Y., Saotome T. et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 2019;37(2):125–34. DOI: 10.1200/JCO.18.00545

27. Di Villeneuve L., Souza I.L., Tolentino F.D.S. et al. Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 2020;10:580141. DOI: 10.3389/fonc.2020.580141

28. Skalova A., Vanecek T., Martinek P. et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol 2018;42(2):234–46. DOI: 10.1097/PAS.0000000000000972

29. Skálová A., Vanecek T., Simpson R.H. et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol 2016;40(1):3–13. DOI: 10.1097/PAS.0000000000000537

30. Drilon A., Li G., Dogan S. et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6- NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016;27(5):920–6. DOI: 10.1093/annonc/mdw042

31. Le X., Baik C., Bauman J. et al. Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist 2022;29(6):e779–88. DOI: 10.1093/oncolo/oyac080

32. Hyman D.M., Tilburg C.M., Albert C.M. et al. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol 2019;30:v159–93.

33. Ardini E., Menichincheri M., Banfi P. et al. Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 2016;15(4):628–39. DOI: 10.1158/1535-7163.MCT-15-0758

34. Rolfo C., Dziadziuszko R., Doebele R.C. et al. 476 PUpdated efficacy and safety of entrectinib in patients with NTRK fusionpositive tumors: integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol 2019;30:v159–93. DOI: 10.1093/annonc/mdz244.038

35. Lu S., De Braud F.G.M., Fan Y. et al. Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours. Ann Oncol 2023;34(Suppl 2):S458–97. DOI: 10.1016/S0923-7534(23)01936-1

36. Imamura Y., Kiyota N., Tahara M. et al. Systemic therapy for salivary gland Malignancy: current status and future perspectives. Jpn J Clin Oncol 2022;52(4):293–302. DOI: 10.1093/jjco/hyac008

37. Linxweiler M., Kuo F., Katabi N. et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res 2020;26(12):2859–70. DOI: 10.1158/1078-0432.CCR-19-3758

38. Cohen R.B., Delord J.P., Doi T. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 2018;41(11):1083–8. DOI: 10.1097/COC.0000000000000429

39. Fayette J., Even C., Digue L. et al. NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J Clin Oncol 2019;37:6083. DOI: 10.1200/JCO.2019.37.15_suppl.6083

40. Even C., Delord J.P., Price K.A. et al. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer 2022;171:259–68. DOI: 10.1016/j.ejca.2022.05.007

41. Niwa K., Kawakita D., Nagao T. et al. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep 2020;10(1):16988. DOI: 10.1038/s41598-020-73965-6

42. Vos J.L., Burman B., Jain S. et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat Med 2023;29(12):3077–89. DOI: 10.1038/s41591-023-02518-x

43. Van Herpen C., Vander Poorten V., Skalova A. et al. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open 2022;7(6):100602. DOI: 10.1016/j.esmoop.2022.100602

44. Kurzrock R., Bowles D.W., Kang H. et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 2020;31(3):412–21. DOI: 10.1016/j.annonc.2019.11.018